Eva Sjökvist Saers has been appointed as the new Chairman of the Board of Directors of Oxcia AB (publ). Oxcia AB has developed the technology platform O2-DDR and is developing new treatments for several serious diseases with the aim of improving and saving lives.
Oxcia AB is a leader in research and development on the use of DNA damage and damage responses caused by oxygen, so-called oxidative damage. With its O2-DDR technology platform, Oxcia aims to develop new treatments for e.g. cancer and inflammation to improve and prolong lifes.
Eva Sjökvist Saers has worked on Oxcia’s Board of Directors since 2020 and has a long industrial life science background at senior level, including within Astra/AstraZeneca and as CEO of the pharmaceutical company APL. Eva Sjökvist Saers currently works on the boards of a number of companies, as chairman of Coegin Pharma AB and Dicot Pharma AB and as a board member of Alligator Bioscience AB, Apoex AB, Bluefish Pharmaceuticals AB and NextCell Pharma AB, as well as chairman of Swelife – a strategic innovation program. Eva is well versed in Oxcia’s business, has a deep understanding of the industry and a broad network.
“It is a great advantage for me to have her by my side in the continued development of Oxcia and the technology platform, O2-DDR.” emphasizes Oxcia’s CEO, Ulrika Warpman Berglund.
The former Chairman of the Board since 2021, Jan Zetterberg, is a co-founder of Oxcia and was its CEO from 2014 to 2020.
“I would like to take this opportunity to express a warm thank you to Jan for very valuable support in the development of Oxcia’s vision and business, for his broad expertise and experience as well as his warm heart,” says Ulrika Warpman Berglund. Jan has really contributed to Oxcia’s progress and ensured that we are firmly anchored in vision, goals and culture – always with strong ethos.”
“It is with great enthusiasm that I take over the baton from Jan,” says Eva Sjökvist Saers. I look forward to our continued joint work to significantly extend and improve the lives of patients affected by serious diseases such as cancer and inflammatory diseases.”
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com